Spots Global Cancer Trial Database for Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
Official Title: Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
Study ID: NCT04706936
Conditions
Study Description
Brief Summary: This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM). CBG-002 is designed based on the fourth-generation of CAR-T techonology.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Contact Details
Name: Wenbin Qian
Affiliation: 2nd Affiliated Hospital, School of Medicine, Zhejiang University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
